Terms ending in 2026
Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,282,588 | Azaindole Inhibitors of Aurora Kinases In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 7,419,988 | Azaindole Inhibitors of Aurora Kinases In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 7,495,102 | Azaindole Inhibitors of Aurora Kinases In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 7,605,266 | Azaindole Inhibitors of Aurora Kinases In force · High confidence | GlaxoSmithKline LLC | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.